MedTrace Logo

BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis

NCT03549416 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2025-03-28

No results posted yet for this study

Summary

The BioDay Registry aims to address the need for daily practice data regarding the effectiveness and safety of new systemic treatment options (like biologics and Janus kinase inhibitors) in patients with atopic dermatitis and effect on other atopic comorbidities in a multicenter setting. The registry already consists of several additional modules concerning atopic comorbidities, like food allergy and asthma, and a module for conjunctivitis during biologic treatment.

Conditions

Sponsors & Collaborators

  • Academisch Ziekenhuis Groningen

    collaborator OTHER

  • Sanofi

    collaborator INDUSTRY

  • AbbVie

    collaborator INDUSTRY

  • Eli Lilly and Company

    collaborator INDUSTRY

  • LEO Pharma

    collaborator INDUSTRY

  • UMC Utrecht

    lead OTHER

Principal Investigators

  • Marjolein de Bruin-Weller, Md, PhD · UMC Utrecht

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03549416 on ClinicalTrials.gov